SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, has scheduled a special webcast event to report on pre-clinical testing of the Aethlon Hemopurifier® in cancer therapy. The webcast will begin at 4:05 pm EDT on Tuesday, July 17th. Aethlon CEO, James A. Joyce will host the event and introduce researchers studying the capability of the Aethlon Hemopurifier® to capture tumor-secreted exosomes, which are known to depress the immune function in cancer patients. Exosomes shield tumor cells from the immune response by inducing T-cell apoptosis (programmed cell death), and blocking T-cell signaling, proliferation, and cytokine production. Exosomes have also been reported to reduce the effectiveness of chemotherapy drugs. The webcast event will be accessible at www.aethlonmedical.com/news/cancer.htm.
